As Novartis Buys Into Gene Therapy, GSK Bows Out With Orchard Deal

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/